Health
Monoclonal antibodies against MERS coronavirus show promise in phase 1 trial – Medical Xpress
A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory…
A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory syndrome (MERS) found that they were well tolerated and generally safe when administered simultaneously to healthy adults. The experimental mAbs, REGN3048 and REGN3051, target the MERS coronavirus (MERS CoV) spike protein used by the virus to attach to and infect target cells. The mAbs were discovered and developed by scientists at the biopharmaceutical…
-
Noosa News17 hours agoSuncorp Stadium upgrades to rival Sydney as seat capacity and infrastructure prioritised
-
Business20 hours agoWhy you should sell CBA, Lynas, and Tabcorp shares today
-
General15 hours agoRescuers pull children from the rubble of Indonesian boarding school collapse
-
Noosa News19 hours agoAnother whale calf caught in Noosa nets